Health and Healthcare

Will This Dementia Treatment Be a Big Hit After FDA Decision?

courtesy of the U.S. Food and Drug Administration

Prevail Therapeutics Inc. (NASDAQ: PRVL) shares jumped early on Tuesday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation (ODD) for its dementia treatment.

Specifically, the designation is for the firm’s gene therapy candidate, PR006, for the treatment of patients with frontotemporal dementia (FTD) with a GRN mutation. There are currently no approved therapies for FTD.

ODD is granted by the FDA to drugs or biologics intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States.

Programs with ODD status receive partial tax credit for clinical trial expenditures, waived user fees and eligibility for seven years of marketing exclusivity.

Asa Abeliovich, M.D., Ph.D., founder and CEO of Prevail, commented:

FTD with a GRN mutation is characterized by progressive difficulties in decision-making, behavior and language. With no approved treatments for FTD, there is an urgent unmet need for therapies that slow or stop this disease. Orphan drug designation is an important milestone as we prepare to bring PR006 into the clinic in the first half of 2020.

Shares of Prevail Therapeutics closed Monday at $15.33, in a 52-week range of $7.41 to $16.90. The consensus price target is $18.33. Following the announcement, the stock was up over 11% at $17.10 in early trading indications Tuesday.


Credit Card Companies Are Doing Something Nuts

Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.

It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.

We’ve assembled some of the best credit cards for users today.  Don’t miss these offers because they won’t be this good forever.

 

Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.